普通外文研报
Plastic Surgeon KOL Roundtable Download - Part 2
研报英文原文证据摘录
Plastic Surgeon KOL Roundtable Download - Part 2
Medical Supplies & Devices
Establishment Labs
TD SECURITIES (USA) LLC COMPANY UPDATE
June 18, 2026
Price: $82.39 (06/17/2026) Plastic Surgeon KOL Roundtable Download -
Price Target: $100.00 (Prior $95.00) Part 2
BUY (1)
ESG SCORE: 48/100
Joshua Jennings, M.D. THE TD COWEN INSIGHT
646 562 1333
Our bull thesis is that ESTA is not merely taking share; it is redefining the standard of care in
joshua.jennings@tdsecurities.com
augmentation around a branded, minimally invasive, premium patient experience enabled by
Colin Clark revolutionary implant technology. We believe Motiva/Ergonomix implants combined with the
646 562 1441 Preservé and Mia MIS techniques have the potential to capture a majority share position and
colin.clark@tdsecurities.com
expand the breast implant TAM.
John Rusch, CFA
646 562 1324 Motiva/Ergonomix and Preservé Are Raising the Bar in Breast Augmentation: The Plastic
john.rusch@tdsecurities.com Surgeon KOL roundtable event we hosted last week strengthens our conviction that
Key Data Establishment Labs is marching toward U.S. market leadership. As we relayed in Part 1 (LINK),
Symbol NASDAQ: ESTA Motiva has achieved early surgeon conversion at a record pace, with the four high-volume
Beta: 1.11 surgeons reporting their moves to near-exclusive use.
52-Week Range: $85.11-$33.62 In Part 2, we are focusing on Preservé as it appears to be expanding the market by converting
Market Cap: $2.4B patients who previously rejected traditional breast augmentation. The minimally invasive
Net Debt (MM): $195.9 surgery (MIS) platform supports premium pricing, higher procedural efficiency, reduced
Cash/Share: $(1.41) downtime, social media-driven awareness, and potentially smoother seasonality. GLP-1-related
Dil.
本摘录由系统从所标注的 PDF 证据页直接提取并保留英文原文,不做批量翻译;登录后在阅读器切换中文时才按需翻译。
打开研报阅读器